Furthermore, investigations with the human monoclonal anti-CD73 antibody MEDI9447 that is currently in Phase I clinical trials, showed high efficacy in inhibiting CD73 in vitro and potent inhibition of pre-clinical syngeneic tumor models in vivo as well as additive activity in combination with immune checkpoint inhibitors. Here, NT5E is linked to neoplasm.